<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
ğŸŒ± ä¾†è‡ª: [[Huppert&rsquo;s Notes]]
 Plasma Cell Disorders #ğŸš§ æ–½å·¥ä¸­ Plasma Cell Disorders A framework for plasma cell disorders:"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Plasma Cell Disorders"><title>Plasma Cell Disorders</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.171424b9c86edb406074af1c7e6a3882.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.af866057de6c2ddc1efb18b647e7fd18.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Plasma Cell Disorders</h1><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Jan 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Plasma%20Cell%20Disorders.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><blockquote class=info-callout><p></p><p>ğŸŒ± ä¾†è‡ª: <a class="internal-link broken">Huppert&rsquo;s Notes</a></p></blockquote><a href=#plasma-cell-disorders--æ–½å·¥ä¸­><h1 id=plasma-cell-disorders--æ–½å·¥ä¸­><span class=hanchor arialabel=Anchor># </span>Plasma Cell Disorders #ğŸš§ æ–½å·¥ä¸­</h1></a><a href=#plasma-cell-disorders><h3 id=plasma-cell-disorders><span class=hanchor arialabel=Anchor># </span>Plasma Cell Disorders</h3></a><p>A framework for plasma cell disorders:</p><p>â€¢Â Â Â Spectrum of disease: See Figure 7.6</p><p>-Â Â Â Monoclonal gammopathy of uncertain significance (MGUS) (asymptomatic)</p><p>-Â Â Â Smoldering multiple myeloma (asymptomatic): &lt;3g/dL M-spike or 10% plasma cells on bone marrow biopsy</p><p>-Â Â Â Active multiple myeloma</p><p>-Â Â Â Plasma cell leukemia</p><p>-Â Â Â Amyloidosis: Some clones make light chains that are amyloidogenic â€“ can occur with any of the four above</p><a href=#monoclonal-gammopathy-of-undetermined-significance-mgus><h5 id=monoclonal-gammopathy-of-undetermined-significance-mgus><span class=hanchor arialabel=Anchor># </span>Monoclonal gammopathy of undetermined significance (MGUS)</h5></a><p>â€¢Â Â Â Pathophysiology: Asymptomatic pre-malignant plasma cell proliferation that typically occurs in elderly patients. See increase in serum protein with M-spike on SPEP, but no other associated symptoms. Fewer than 20% of patients with MGUS develop multiple myeloma (MM), but almost all patients with MM have preceding MGUS.</p><p>â€¢Â Â Â Diagnostic criteria:</p><p>-Â Â Â Serum monoclonal Ig protein (M-spike) &lt;3 g</p><p><strong>FIGURE 7.6: Spectrum of plasma cell dyscrasias</strong>.</p><p>-Â Â Â Bone marrow clonal plasma cells &lt;10%</p><p>-Â Â Â No end organ damage (i.e., no CRAB criteria)</p><p>â€¢Â Â Â Work-up:</p><p>-Â Â Â CBC, CMP, Mg2+, phosphorus, LDH, total immunoglobulins (IgA, IgG, IgM)</p><p>-Â Â Â Serum protein electrophoresis (SPEP) â€“ <em>quantifies</em> a monoclonal abnormal protein (M-spike)</p><p>-Â Â Â Immunofixation (IFE) â€“ <em>classifies</em> the abnormal protein</p><p>-Â Â Â Serum free light chain (sFLC) â€“ Detects LOW levels of free light chains in serum, so it can pick up lighter proteins. Note: In CKD, increased K:L ratio up to 3 can be normal due to â†“clearance of FLC</p><p>-Â Â Â UA, urine spot protein/Cr.</p><p>-Â Â Â 24hr UPEP â€“ <em>quantifies</em> urine M protein, UIFE â€“ <em>classifies</em> abnormal protein, urine free light chains (Bence Jones protein)</p><p>-Â Â Â Beta-2-microglobulin: Strong prognostic value but non-specific</p><p>-Â Â Â Skeletal survey (long bones, skull) to rule out lytic lesions suggesting multiple myeloma. Alternatively, can consider low dose whole body CT scan or MRIs.</p><p>â€¢Â Â Â Treatment: None needed, observation. Monitoring depends on risk factors (Ig type, M-spike, light chains).</p><a href=#multiple-myeloma-mm><h5 id=multiple-myeloma-mm><span class=hanchor arialabel=Anchor># </span>Multiple myeloma (MM)</h5></a><p>â€¢Â Â Â Pathophysiology: Malignant proliferation of a single plasma cell line that makes a monoclonal immunoglobulin â€“ most often large amounts IgG or IgA</p><p>â€¢Â Â Â Clinical features: Often patients in 60s with fractures or bone pain</p><p>-Â Â Â Diagnostic criteria = <strong>SLiM-CRAB</strong></p><p><strong>â€¢</strong>Â Â Â <strong>S</strong>ixty percent plasma cells on bone marrow biopsy</p><p><strong>â€¢</strong>Â Â Â Serum Free <strong>Li</strong>ght chain ratio >100</p><p><strong>â€¢</strong>Â Â Â <strong>M</strong>RI with >1 focal lesion (plasmacytoma)</p><p><strong>â€¢</strong>Â Â Â Hyper<strong>C</strong>alcemia (>10.5 mg/dL)</p><p><strong>â€¢</strong>Â Â Â <strong>R</strong>enal insufficiency (immunoglobulins precipitate in renal tubules - Bence Jones protein, Cr >2mg/dL without an alternative diagnosis)</p><p><strong>â€¢</strong>Â Â Â <strong>A</strong>nemia (Hgb&lt;10 g/dL without an alternative diagnosis)</p><p><strong>â€¢</strong>Â Â Â <strong>B</strong>ony disease (â€œpunched outâ€ lytic bone lesions or osteoporosis). Bone pain most common presenting symptom.</p><p>-Â Â Â Other clinical features:</p><p><strong>â€¢</strong>Â Â Â Amyloidosis: Kappa chain accumulation â†’ carpal tunnel syndrome</p><p><strong>TABLE 7.4</strong> â€¢ R-ISS Staging for Multiple Myeloma: Criteria and Prognosis</p><p><strong>â€¢</strong>Â Â Â Infection: Lack of immunoglobulin diversity can lead to increased risk of infection</p><p>â€¢Â Â Â Diagnosis: Need labs (SPEP, SFLC), imaging (usually PET/CT), and bone marrow biopsy</p><p>-Â Â Â Serum monoclonal protein present (M-spike >3g)</p><p>-Â Â Â Bone marrow clonal plasma cells >10%</p><p>-Â Â Â End organ damage present (i.e., SLiM-CRAB)</p><p>-Â Â Â Other common findings:â†‘ESR, â†‘serum protein. Smear: RBC = Rouleaux (â€œstacks of RBCsâ€ â€“ RBCs stick together due to increased plasma proteins)</p><p>â€¢Â Â Â Staging: Revised-International Staging System (R-ISS): Uses Beta-2-microglobulin, albumin, LDH, and chromosomal abnormalities to predict overall and progression-free survival at 5 yr. See Table 7.4.</p><p>â€¢Â Â Â Treatment: Typically, chemotherapy followed by autologous stem cell transplant</p><p>-Â Â Â Classes of therapy:</p><p><strong>â€¢</strong>Â Â Â Proteasome inhibitors: Bortezomib, carfilzomib</p><p><strong>â€¢</strong>Â Â Â Immunomodulatory agents: Lenalidomide</p><p><strong>â€¢</strong>Â Â Â Monoclonal Antibody: Daratumumab (anti-CD38 targeting MM cells)</p><p>-Â Â Â Common regimens:</p><p><strong>â€¢</strong>Â Â Â Hyper CD (cyclophosphamide + dexamethasone) â€“ commonly used for rapid reduction in patients with a high disease burden</p><p><strong>â€¢</strong>Â Â Â RVD: lenalidomide (Revlimid), bortezomib (Velcade), dexamethasone</p><p><strong>â€¢</strong>Â Â Â KRD: carfilzomid (Kyprolis), lenalidomide (Revlimid), dexamethasone</p><p><strong>â€¢</strong>Â Â Â Daratumumab, lenalidomide, dexamethasone</p><a href=#waldenstrÃ¶m-macroglobulinemia><h5 id=waldenstrÃ¶m-macroglobulinemia><span class=hanchor arialabel=Anchor># </span>WaldenstrÃ¶m macroglobulinemia</h5></a><p>â€¢Â Â Â Pathophysiology: Malignant clonal proliferation of IgM producing plasmacytoid lymphocytes</p><p>â€¢Â Â Â Clinical features: Similar to MM, but IgM protein is larger and â€œstickier,â€ so it causes more symptoms of hyperviscosity syndrome (up to 30% of patients). Cold cryoglobulinemia in 10% of patients.</p><p>â€¢Â Â Â Treatment: Plasmapheresis may be needed to emergently manage hyperviscosity. Treatment usually includes rituximab.</p><a href=#al-amyloidosis><h5 id=al-amyloidosis><span class=hanchor arialabel=Anchor># </span>AL amyloidosis</h5></a><p>â€¢Â Â Â Pathophysiology: Immunoglobulin light chain amyloid from malignant clonal proliferation of plasma cells (e.g., MM, WaldenstrÃ¶m). The proteins deposit in tissues and cause end organ damage.</p><p>â€¢Â Â Â Clinical features: Nephrotic syndrome, restrictive cardiomyopathy, neuropathy</p><p>â€¢Â Â Â Diagnosis: Biopsy (often fat pad biopsy) to look for deposition of amyloid protein. SPEP will show an M-spike and serum free light chains will show an abnormal sFLC ratio.</p><p>â€¢Â Â Â Treatment: Treat underlying plasma cell disorder. Consider autologous stem cell transplant.</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li><a href=/Hematopoietic-Disorders/ data-ctx="Plasma Cell Disorders" data-src=/Hematopoietic-Disorders class=internal-link>Hematopoietic Disorders</a></li><li><a href=/hematology/ data-ctx="Plasma Cell Disorders" data-src=/hematology class=internal-link>hematology</a></li><li><a href=/hematology-of-Hupperts-Notes/ data-ctx="Plasma Cell Disorders" data-src=/hematology-of-Hupperts-Notes class=internal-link>hematology of Huppert's Notes</a></li><li><a href=/inbox/ data-ctx="Plasma Cell Disorders" data-src=/inbox class=internal-link>inbox</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>